The disruption of normal gene expression underlies many human diseases
Returning gene expression to normal levels could provide a path to treating virtually any disease. Until now, no company has deciphered the complex rules of the cellular system driving gene expression.
Our Gene Circuitry PlatformTM is the first approach capable of mapping the transcriptional machinery and network of signaling pathways that control gene expression across any cell in the human body. We are systematically discovering all the targets that can be engaged to either dial up or down unhealthy gene expression. Using our circuitry maps, we can precisely explain the relationship between any drug target and the gene on which it acts, allowing us to quickly advance new drug candidates into development.
Each cell type in the human body uses a sophisticated process to orchestrate the vast number of interrelated transcriptional components that control the expression of our genes.
Millions of Cells and Hundreds of Signals
13,000 Gene Loops
2,000 Transcription Factors
By systematizing next-generation sequencing techniques in concert with our proprietary approach to characterizing gene expression, CAMP4 generates terabytes of wet lab data to elucidate these components. We then apply machine learning to identify the key signals tied to the transcriptional machinery, forming the basis of our proprietary Gene Circuitry MapsTM.
CAMP4 enables faster drug discovery and development across multiple dimensions by determining pathway and target prioritization in a click, ultimately across many different cell types and therapeutic areas. We intend for our approach to displace the traditional, bespoke drug discovery process with one that is streamlined, efficient and systematic.
Once a cell map is created, we can quickly identify pathways and druggable targets to control the output of any gene of interest. The process is rapid and repeatable for any disease-associated gene expressed in a mapped cell, allowing us to move from target identification to lead optimization in a fraction of the time vs traditional methods.
Our goal is to displace the traditional, bespoke target identification process with one that is streamlined and efficient. We believe our systematic approach will translate to far better success rates than the current drug discovery and development process yields, reducing the time and cost to move a drug candidate from discovery to approval.
Most importantly, our approach has the potential to create hundreds of new treatments for patients, with the long-term aspiration of unlocking a treatment for every disease.